Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Proposed Megamerger Between Pfizer and Allergan



Should the companies proceed with the merger, some have speculated that US-based Pfizer would relocate to Ireland – currently the home of Allergan – in order to take advantage of a lower tax rate.

Share this!

November 2, 2015 | by Sarah Massey, M.Sc.

Pfizer and Allergan have announced that they’re considering a merger which could afford Pfizer a 10 percent tax break. Should the companies proceed with the merger, some have speculated that US-based Pfizer would relocate to Ireland – currently the home of Allergan – in order to take advantage of a lower tax rate.

The talks have reintroduced the topic of inversions – the relocation of an American company to a country with a lower tax rate – into the media spotlight. According to Reuters, Pfizer is currently taxed at 24%, while Allergan only pays 15% tax on their revenue.

Last year, the Obama administration outlined the steps the government planned to make in order to make it harder for companies to perform corporate inversions. The new rules were put in place by the White House in an attempt to keep the tax dollars coming in on US soil.

As numerous companies have already committed inversion for the tax benefits, some are wondering whether the Obama administration will step in to prevent the Pfizer-Allergan merger from happening. With the current political climate in the US and a new president expected to come into power next year, some are wondering whether the pharmaceutical companies will bide their time.

According to treasury secretary Jacob Lew, inversions are “an unfair loophole.” The new regulations regarding corporate relocation were released in September 2014, with the toughest rule being that a US-based company cannot own more than 80% or a foreign company that is acquired in a merger.

Along with other complicated calculations involving earnings of overseas subsidiaries, the new regulations are designed to make inversion much more difficult for corporations. Despite these tough regulations, industry insiders point out that the rule can be circumvented if the foreign company were to acquire the US-based firm.

In the case of proposed Pfizer-Allergan merger, Pfizer is the larger corporation so it’s unlikely that Allergan would mount a takeover. Big Pharma is no stranger to inversion but the Pfizer-Allergan merger would be the largest ever, if it’s allowed to proceed.

According to Representative Sandy Levin, who is the top Democrat on the House Ways and Means Committee, “As companies continue to contemplate possible tax inversions, it is our responsibility to act to address this loophole once and for all.” The proposed merger would cost the US economy hundreds of billions of dollars as well as thousands of jobs, according to investor Carl Icahn.




The Use of High Resolution Accurate Mass Spectrometry

Gain Control of Your Packaging Supply Chain

Keywords:  Pfizer, Allergan, Merger


Share this with your colleagues!

Herpes Infection More Common Than Previously Thought

October 30, 2015 - Recent research shows that over 3.7 billion people under the age of 50 are infected with the virus that commonly causes ‘cold sores’ and is capable of causing genital herpes – herpes simplex virus type 1.

Widely-Used Acid Reflux Drugs Could Increase Risk Of Kidney Disease

October 29, 2015 - According to two new studies – to be presented at ASN Kidney Week 2015 November 3-8 at the San Diego Convention Center in San Diego, CA – certain popular acid reflux medications could increase an individual’s risk of developing kidney disease.

Snake Venom-Containing Hydrogels To Control Bleeding

October 29, 2015 - Rice University scientists have developed a nanofiber hydrogel containing snake venom, as a procoagulant to be used to control bleeding.

Copyright © 2016-2017 Honeycomb Worldwide Inc.